COVID-19: Current Impact of the Pandemic on Pharmaceutical Companies MAY 2020 Nishika Bhan, MSc, Shweta Dudeja, MSc and Aviral Maheshwari, MBA, MS, MBBS Note: Given that the situation is continually evolving, the thoughts and opinions are formulated to keep the...
COVID-19:Clinical Trial Management During the Pandemic MAY 2020 Jyotsana Chaudhary, MSc, Jatin Gupta, MSc and Sukanya Saha, MSc Note: Given that the situation is continually evolving, the thoughts and opinions are formulated to keep the current situation in mind....
Would your client engagement strategy pass the Darwin test during these extraordinary times? APRIL 2020 Jamie Denison-Pender CEO Charles Darwin would have been fascinated to sit back and observe how our society evolves to cope with the challenges posed by the...
Sad that COVID-19 is causing your favorite medical congresses to cancel? Don’t be. Virtual congresses are delivering all your favorites, and you can attend in pajamas! MARCH 2020 Tanya Casimiro, PhD and Malvika Saharya, OD Is your life the space between ASCO and ASH?...
COVID-19: The Impact on Biopharmaceutical Companies MARCH 2020 Jyotsana Chaudhary, Jatin Gupta and Dr. Ashima Sharma Note: The COVID-19 situation is continually evolving; the thoughts and opinions expressed here were formulated based on the situation as of...
By: Shweta Srivastava and Anil Sharma Tumor mutational burden (TMB (the number of mutations per megabase of DNA (mut/Mb)) can be a predictor of response for single-agent immunotherapy, but it has failed to demonstrate any correlation with response when immunotherapy...
